We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Universal Health Grows on Acquisitions, Rising Debt a Drag
Read MoreHide Full Article
Universal Health Services, Inc.'s (UHS - Free Report) inorganic strategies substantially make it well positioned for long-term growth. Universal Health has been witnessing revenue growth for a long time, primarily driven by its frequent and strategic acquisitions and mergers. In 2016, the company acquired the adult services division of Cambian Group.
Universal Health specializes in providing care to underprivileged patients at low costs. Its acute care platform has been delivering strong underwriting results. Continuing the trend, in the first quarter of 2017, net revenue from acute care hospitals increased 4.8% year over year to $1.4 billion, accounting for 53.8% of the total revenue.
The company’s solid behavioral platform also continues to impress. In fact, behavioral facility acquisitions help Universal Health win market share in the fast growing addiction and mental health disorder market. In the first quarter of 2017, the segment’s revenues (46.2% of total revenue) rose 1.4% year over year to $1.2 billion.
The stock currently has a trailing 12-month P/B ratio of 2.32. This is at the lower end of its range of 2.20 to 3.61 in the same time frame. Moreover, it compares favorably with the market at large, as the current P/B ratio for the S&P 500 is at 3.64. This suggests that the company is undervalued compared to its peers.
However, year to date, the stock has lost 13.2%, underperforming the Zacks categorized Medical-Hospitals industry’s decline of 3.3%. This underperformance was likely due to the company’s exposure to integration risks owing to several acquisitions, highly leveraged balance sheet, and margin contraction at both acute care and behavioral hospitals as well as surging operating expenses.
In addition, the company’s high-debt level has raised concerns over the last five years. This also led to rise in interest expenses.
Another area of concern for the company is the continuous increase in its operating expenses since 2013 which continued to rise in the first quarter of 2017 as well.
Align Technology, a medical dental supplies company, topped estimates in each of the last four quarters with an average beat of 59.23%.
Inogen is a medical instruments seller, which delivered positive surprises in each of the last four quarters with an average beat of 82.42%.
EDAP TMS also posted positive surprises in two of the last four quarters with an average beat of 366.67%
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Universal Health Grows on Acquisitions, Rising Debt a Drag
Universal Health Services, Inc.'s (UHS - Free Report) inorganic strategies substantially make it well positioned for long-term growth. Universal Health has been witnessing revenue growth for a long time, primarily driven by its frequent and strategic acquisitions and mergers. In 2016, the company acquired the adult services division of Cambian Group.
Universal Health specializes in providing care to underprivileged patients at low costs. Its acute care platform has been delivering strong underwriting results. Continuing the trend, in the first quarter of 2017, net revenue from acute care hospitals increased 4.8% year over year to $1.4 billion, accounting for 53.8% of the total revenue.
The company’s solid behavioral platform also continues to impress. In fact, behavioral facility acquisitions help Universal Health win market share in the fast growing addiction and mental health disorder market. In the first quarter of 2017, the segment’s revenues (46.2% of total revenue) rose 1.4% year over year to $1.2 billion.
The stock currently has a trailing 12-month P/B ratio of 2.32. This is at the lower end of its range of 2.20 to 3.61 in the same time frame. Moreover, it compares favorably with the market at large, as the current P/B ratio for the S&P 500 is at 3.64. This suggests that the company is undervalued compared to its peers.
However, year to date, the stock has lost 13.2%, underperforming the Zacks categorized Medical-Hospitals industry’s decline of 3.3%. This underperformance was likely due to the company’s exposure to integration risks owing to several acquisitions, highly leveraged balance sheet, and margin contraction at both acute care and behavioral hospitals as well as surging operating expenses.
In addition, the company’s high-debt level has raised concerns over the last five years. This also led to rise in interest expenses.
Another area of concern for the company is the continuous increase in its operating expenses since 2013 which continued to rise in the first quarter of 2017 as well.
Zacks Rank & Key Picks
Universal Health presently has a Zacks Rank #3 (Hold). Investors can consider some better-ranked stocks like Align Technology, Inc. (ALGN - Free Report) , EDAP TMS S.A. (EDAP - Free Report) and Inogen Inc. (INGN - Free Report) . All of the stocks sport a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, a medical dental supplies company, topped estimates in each of the last four quarters with an average beat of 59.23%.
Inogen is a medical instruments seller, which delivered positive surprises in each of the last four quarters with an average beat of 82.42%.
EDAP TMS also posted positive surprises in two of the last four quarters with an average beat of 366.67%
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>